CENTRAL GARDEN & PET CO 8-K

What Happened Central Garden & Pet Company (CENT) filed an 8-K disclosing multiple governance and capital-return actions. On February 12, 2026 the Board appointed Kay M. Schwichtenberg to the Board effective March 1, 2026; she previously served as the Company’s Executive Vice President, Animal & Public Health (April 2014–Feb 2023) and held prior leadership roles including President & CEO of Central Life Sciences. The Compensation Committee approved cash bonus payments to the Company’s named executive officers for fiscal 2025 (amounts were finalized after the company’s proxy filing). At the February 11, 2026 annual meeting shareholders elected the nine director nominees, ratified Deloitte & Touche LLP as auditor, and approved the advisory vote on executive compensation. The Company also announced an increase in its share repurchase authorization such that, as of February 11, 2026, total repurchase capacity is approximately $127 million.

Key Details

• Director appointment: Kay M. Schwichtenberg (age 73), Board appointment effective March 1, 2026; will join the Audit Committee and receive standard director cash and equity compensation. No related-party transactions or special arrangements reported.
• Executive bonuses: Compensation Committee approved FY2025 cash bonuses for named executive officers on February 11, 2026; these amounts were not included in the company’s proxy because they were determined after the proxy filing.
• Shareholder votes (Feb 11, 2026): All nine director nominees were elected; auditor ratification passed 17,177,566 for / 230,538 against (2,009 abstain); advisory "say-on-pay" passed 16,346,943 for / 218,084 against (70,794 abstain) with 361,184 broker non-votes.
• Buyback program: Total repurchase authorization increased to about $127M as of Feb 11, 2026; repurchases may occur on the open market, in private transactions or under Rule 10b5-1 plans; program has no expiration and may be changed or suspended by the Company.

Why It Matters Board changes and Audit Committee additions affect corporate oversight; adding an experienced former executive like Ms. Schwichtenberg may influence governance and industry expertise at the board level. Fiscal 2025 bonus approvals affect executive compensation expense and will be disclosed in required filings, which investors may monitor for trends in pay-for-performance. The shareholder votes show majority support for management (auditor ratification and say-on-pay passed), which reduces near-term governance uncertainty. The increased repurchase authorization signals management’s intent to return capital to shareholders or offset dilution, but timing and the number of shares to be repurchased remain unspecified.